While Christine has MS, she is fortunate in two important respects. One, a wide range of safe and effective MS therapies have become available since she was diagnosed. Two, starting on one of these therapies early in the disease progression—which was the case with her—has been proven to prevent long-term disability.
Over the past 15+ years, Dr. Klawiter has prescribed Christine a series of medications based on how she is doing and what, if any, side effects she is having. Recently, she began taking an injection that requires just a 60- to 90-minute visit to a local infusion center twice a year.
"As the treatment landscape has evolved, we have more options to offer patients," Dr. Klawiter said. "If one treatment doesn't produce the desired results, we can quickly pivot to another one that hopefully will be more effective."
Dr. Klawiter is committed to conducting research to drive breakthroughs in understanding, diagnosing, and treating MS. In fact, Mass General was one of the sites that participated in a clinical trial of ocrelizumab (the drug that Christine is now on) that led to its approval by the U.S. Food and Drug Administration.
"One strength of our center is our ability to fuse great clinical care with research and thus to offer novel new treatments to patients," Dr. Klawiter said. "Another is our comprehensive care model, where we bring in the expertise of other disciplines like specialized MS nursing, rehabilitation with physical therapy and occupational therapy, neuro-ophthalmology, and urology to best treat every patient's individual needs."